RELMADA THERAPEUTICS, INC. (RLMD) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 21 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 12, 2026after close 43 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Tue, May 12, 2026after close 42 8-K
Q4 FY2025Fri, Mar 20, 2026after close 79 8-K
Q3 FY2025Thu, Nov 13, 2025after close 44 8-K
Q2 FY2025Thu, Aug 7, 2025after close 38 8-K
Q4 FY2024Thu, Mar 27, 2025after close 86 8-K
Q4 FY2023Tue, Mar 19, 2024after close 79 8-K

What they guided beta

Q3 FY2026 "NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance" exhibit
Q3 FY2026 "Cash, cash equivalents and short-term investments of approximately $202.1 million as of September 30, 2026, expected to fund operations through 2029" exhibit
Q3 FY2026 "“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026." exhibit
Q3 FY2026 "The Company’s current cash, cash equivalents, and short-term investments as of September 30, 2026, are expected to provide sufficient resources to fund Company operations through 2029, including completion of the two registrational cohorts of the NDV-01 Phase 3 SPECTRUM program." exhibit
Q3 FY2026 "The Company expects to submit an IND by year-end 2026 and initiate the Phase 3 SPECTRUM program upon IND clearance." exhibit
Q2 FY2026 "Advancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway." exhibit
Q2 FY2026 "Sepranolone IND filing expected by year-end 2026 and initiation of Phase 2 proof-of-concept study in Prader-Willi Syndrome upon IND clearance." exhibit
Q2 FY2026 "Cash balance of $217.7 million as of June 30, 2026, expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program." exhibit
Q2 FY2026 "The Company expects to submit the NDV-01 IND by year-end 2026 and initiate the Phase 3 RESCUE registrational program upon IND clearance." exhibit
Q2 FY2026 "This is the remaining step ahead of the sepranolone IND submission, which is expected by year-end 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/RLMD
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/RLMD

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

RLMD earnings date badge

HTML

<a href="https://veritasdata.dev/company/RLMD/"><img src="https://veritasdata.dev/embed/RLMD.svg" alt="RLMD earnings date" width="240" height="56"></a>

Markdown

[![RLMD earnings date](https://veritasdata.dev/embed/RLMD.svg)](https://veritasdata.dev/company/RLMD/)

Script

<script async src="https://veritasdata.dev/embed/RLMD.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/RLMD"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.